|Dr. Kimberly Lynn Blackwell M.D.||CEO & Director||1.12M||N/A||1969|
|Mr. Cameron S. Gallagher M.B.A.||Co-Founder, President & Director||767.69k||N/A||1970|
|Ms. Melissa B. Epperly M.B.A.||CFO & Treasurer||721.64k||N/A||1978|
|Ms. Andrea Paul J.D.||General Counsel & Corporate Secretary||668.2k||N/A||1981|
|Dr. Carrie Brownstein M.D.||Chief Medical Officer||755.06k||N/A||1970|
|Dr. Mark Lackner Ph.D.||Chief Translational Officer & Head of Biomarker Strategy and Chief Scientific Officer||N/A||N/A||1967|
|Ms. Kimberly Freeman||Chief Strategy Officer||N/A||N/A||N/A|
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics: and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
Zentalis Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 December 2023 is 10. The pillar scores are Audit: 6; Board: 4; Shareholder rights: 8; Compensation: 10.